Most Read Articles
Elvira Manzano, 24 Jun 2015
Adding sitagliptin, a dipeptidyl peptidase 4 inhibitor (DPP-4), to usual care in patients with glycaemic equipoise does not increase the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), according to the TECOS* study.
Christina Lau, 15 Jun 2016
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant reductions in major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk in the LEADER (Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcomes Results) trial.
Elvira Manzano, 21 Nov 2016
Newer metabolic agents, including trimetazidine, represent ancillary forms of prophylactic antianginal therapy and may be useful in patients with stable coronary artery disease (SCAD) who are unsuitable for percutaneous or surgical revascularization, says a leading cardiologist at the recent AFCC 2016.
Pearl Toh, 14 Jun 2016
Cardiovascular magnetic resonance (CMR) is a stronger predictor of major adverse cardiovascular events (MACE) compared with single-photon emission computed tomography (SPECT), according to the CE-MARC* study.

Focus on CV Safety of NSAIDs

24 Apr 2017
Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used to treat pain and inflammation in patients with arthritis, but the vascular effects of some NSAIDs have cast doubt on whether they can be used in patients at risk for cardiovascular (CV) disease. At the American Heart Association’s Scientific Sessions 2016 held recently in New Orleans, Louisiana, US, Professor Steven Nissen of the Cleveland Clinic in Cleveland, Ohio, US, presented latest data from the PRECISION (Prospective Randomized Evaluation of Celecoxib Integrated Safety vs Ibuprofen or Naproxen) trial that evaluated the CV risk and safety profile of the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib vs nonselective NSAIDs.

Click here for the full report/supplement

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 24 Jun 2015
Adding sitagliptin, a dipeptidyl peptidase 4 inhibitor (DPP-4), to usual care in patients with glycaemic equipoise does not increase the risk of cardiovascular (CV) events in patients with type 2 diabetes (T2D) and cardiovascular disease (CVD), according to the TECOS* study.
Christina Lau, 15 Jun 2016
Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated significant reductions in major adverse cardiac events (MACE) in patients with type 2 diabetes mellitus (T2DM) at high cardiovascular (CV) risk in the LEADER (Liraglutide Effect and Action in Diabetes – Evaluation of Cardiovascular Outcomes Results) trial.
Elvira Manzano, 21 Nov 2016
Newer metabolic agents, including trimetazidine, represent ancillary forms of prophylactic antianginal therapy and may be useful in patients with stable coronary artery disease (SCAD) who are unsuitable for percutaneous or surgical revascularization, says a leading cardiologist at the recent AFCC 2016.
Pearl Toh, 14 Jun 2016
Cardiovascular magnetic resonance (CMR) is a stronger predictor of major adverse cardiovascular events (MACE) compared with single-photon emission computed tomography (SPECT), according to the CE-MARC* study.